Status:
WITHDRAWN
PDE5i Use in Renal Transplant Recipients
Lead Sponsor:
University of British Columbia
Conditions:
Renal Transplant Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Ischemia-reperfusion (IRI) injuries are common in renal transplantation and cause poor patient outcomes. Ischemia occurs after the donor's death and reperfusion occurs after kidney implantation. The d...
Detailed Description
1. Purpose Renal ischemia-reperfusion injuries (IRI) are the result of multifactorial mechanisms. During ischemia, the kidney is subject to reduced blood flow, oxygen delivery, and nutrients. This lea...
Eligibility Criteria
Inclusion
- renal transplant patients at VGH undergoing donation after circulatory death (DCD) and donation after brain death (DBD) kidney transplants
- 19 years of age
- able to provide consent.
Exclusion
- Patients that are unable to understand the purpose of the study or cannot give written consent will be excluded.
- Moreover, patients with contraindications to PDE5 inhibitors will be excluded from the study. PDE5 inhibitors are generally well tolerated, even in patients with severe renal disease, those on dialysis, and in transplant recipients. Patients will be excluded if they are taking nitrates of any form (contraindication), are allergic to sildenafil or any of the ingredients of this medication, are on an alpha-adrenergic blocker (potential risk)
- patients currently on any experimental drug in the last 3 months (confounding factor).
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04122105
Start Date
April 1 2021
End Date
January 1 2023
Last Update
May 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver General Hospital
Vancouver, British Columbia, Canada, V6N2A2